AVROBIO Inc. (NASDAQ:AVRO) shares traded -1.40% lower at $1.41 on Wall Street last session.
In accordance with the data, 7 analysts cover AVROBIO Inc. (NASDAQ:AVRO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $3.00. Given the previous closing price of $1.43, this indicates a potential upside of 109.79 percent. AVRO stock price is now 46.33% away from the 50-day moving average and 50.06% away from the 200-day moving average. The market capitalization of the company currently stands at $61.72M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 2 analysts and a buy by 4. Brokers who have rated the stock have averaged $3.50 as their price target over the next twelve months.
Insiders disposed of 245,123 shares of company stock worth roughly $0.35 million over the past 1 year. A total of 2.66% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AVRO stock. A new stake in AVROBIO Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $917,000. VIRTU FINANCIAL LLC invested $57,000 in shares of AVRO during the first quarter. In the first quarter, TANG CAPITAL MANAGEMENT LLC acquired a new stake in AVROBIO Inc. valued at approximately $53,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in AVRO for approximately $34,000. CITIGROUP INC purchased a new stake in AVRO valued at around $28,000 in the second quarter. In total, there are 65 active investors with 56.00% ownership of the company’s stock.
AVROBIO Inc. (NASDAQ: AVRO) opened at $1.3600 on Thursday. During the past 12 months, AVROBIO Inc. has had a low of $0.56 and a high of $1.93. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for AVRO is $0.9752 and a two-hundred day moving average price translates $0.9431 for the stock.
The latest earnings results from AVROBIO Inc. (NASDAQ: AVRO) was released for Mar, 2023.
AVROBIO Inc.(AVRO) Company Profile
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company’s pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
